Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study

作者：Baozhen Wang, Xiaoyi Hao, Yang Yu, Wenwen Cao, Dangui Huang, Guangping Xie, Shan Yang, Hong Zhao, Ying Zhang, Hui Hao, Yaxin Zhang · 发表于：Echocardiography · 年份：2025 · DOI：10.1111/echo.70339 · 被引用次数：1 · 研究领域：Cardiovascular Function and Risk Factors、Chemotherapy-induced cardiotoxicity and mitigation、Atrial Fibrillation Management and Outcomes

OBJECTIVE: This study aimed to determine whether left atrial (LA) strain can identify early alterations in LA function in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP chemotherapy regimen and whether these alterations can prospectively predict the subsequent development of cancer therapy-related cardiac dysfunction (CTRCD). METHODS: DLBCL patients scheduled to receive the R-CHOP regimen were prospectively recruited for this study. Echocardiography was performed at T0 (pre-chemotherapy), T1 (after the third cycle), T2 (end of 6-8 cycles), and T3 (1-year post-T2). Left ventricular global longitudinal strain (LV GLS), LA reservoir strain (LASr), LA conduit strain (LAScd), LA contraction strain (LASct), and LA stiffness index (LASI) were calculated using speckle tracking echocardiography (STE). Patients were divided into CTRCD and non-CTRCD groups based on a > 15% reduction in LV GLS. RESULTS: Seventeen patients (23.6%) developed to CTRCD after chemotherapy. Patients who developed CTRCD were relatively older (67 [57-71] vs. 60 [49-68], p < 0.05). A significant deterioration in LASr, LAScd, and LASI at T1 persisted throughout the follow-up period. Relative changes in LASr (≥ 23.4%) and LASI (≥ 20.0%) were robust predictors of subsequent CTRCD development. The LASr > 35% criterion in the validation cohort demonstrated substantial agreement with the 2016 ASE guidelines. CONCLUSION: LASr and LASI effectively identify early alterations in LA function in DLBCL pat...